Neurostimulation Devices | Market Insights | US | 2024
The US neurostimulation device market is characterized by ongoing product innovation; iterative device improvements are regularly launching in established segments—such as the SCS and DBS device markets—while emerging novel products, such as closed-loop SCS devices and minimally invasive tibial nerve stimulation devices, are becoming available. Although the market continued to see a negative impact from the COVID-19 pandemic and hospital staffing shortages in 2022, it is positioned to expand strongly going forward, supported by rapid adoption of minimally invasive technologies and device use in expanding indications, such as SCS treatment of painful diabetic neuropathy.
This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurostimulation devices in the US from 2019 through 2032.
